胃肠道间质瘤的分子基础与治疗。
Molecular basis and management of gastrointestinal stromal tumors.
机构信息
Division of Hematology and Oncology, Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Ave, St 3300, Miami, FL 33136, USA.
出版信息
World J Gastroenterol. 2010 Jun 14;16(22):2726-34. doi: 10.3748/wjg.v16.i22.2726.
Abstract
Molecularly targeted agents have dramatically impacted the management of several cancers. Targeting KIT has led to a new treatment paradigm in gastrointestinal stromal tumors (GISTs). KIT is a cell surface receptor with tyrosine kinases that, upon binding of its ligand, stem cell factor, activates various signaling pathways. Imatinib and sunitinib, both tyrosine kinase inhibitors directed to KIT, were approved for first- and second-line treatment of metastatic and unresectable GISTs. In this article, we will review the molecular pathogenesis of GISTs followed by a discussion of imatinib and sunitinib's role in the treatment of GISTs. Finally, we will introduce novel therapeutic options for imatinib- and sunitinib-resistant GISTs.
摘要
分子靶向药物极大地改变了多种癌症的治疗方式。针对 KIT 的治疗已经为胃肠道间质瘤（GISTs）带来了新的治疗范例。KIT 是一种细胞表面受体，具有酪氨酸激酶，当它的配体干细胞因子结合时，会激活各种信号通路。伊马替尼和舒尼替尼，这两种针对 KIT 的酪氨酸激酶抑制剂，被批准用于转移性和不可切除的 GISTs 的一线和二线治疗。在本文中，我们将回顾 GISTs 的分子发病机制，然后讨论伊马替尼和舒尼替尼在 GISTs 治疗中的作用。最后，我们将介绍针对伊马替尼和舒尼替尼耐药的 GISTs 的新的治疗选择。
相似文献
1
Molecular basis and management of gastrointestinal stromal tumors.胃肠道间质瘤的分子基础与治疗。
World J Gastroenterol. 2010 Jun 14;16(22):2726-34. doi: 10.3748/wjg.v16.i22.2726.
2
The role of KIT in the management of patients with gastrointestinal stromal tumors.KIT在胃肠道间质瘤患者管理中的作用。
Hum Pathol. 2007 May;38(5):679-87. doi: 10.1016/j.humpath.2007.03.001.
3
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.舒尼替尼作为伊马替尼治疗失败后的晚期 GISTs 的二线治疗：韩国患者疗效与肿瘤基因型的关系。
Invest New Drugs. 2012 Apr;30(2):819-27. doi: 10.1007/s10637-010-9593-1. Epub 2010 Nov 23.
4
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].[胃肠道间质瘤：分子层面及治疗意义]
Bull Cancer. 2008 Jan;95(1):107-16. doi: 10.1684/bdc.2008.0561.
5
[Consensus on the medical treatment of gastrointestinal stromal tumors].[胃肠间质瘤的医学治疗共识]
Zhonghua Zhong Liu Za Zhi. 2007 Nov;29(11):875-7.
6
KIT mutations in GIST.胃肠道间质瘤中的KIT基因突变
Curr Opin Genet Dev. 2007 Feb;17(1):3-7. doi: 10.1016/j.gde.2006.12.010. Epub 2007 Jan 8.
7
Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.氟马替尼是一种 BCR-ABL/PDGFR/KIT 的选择性抑制剂，能有效克服某些 KIT 突变体的耐药性。
Cancer Sci. 2014 Jan;105(1):117-25. doi: 10.1111/cas.12320. Epub 2014 Jan 4.
8
Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.舒尼替尼治疗伊马替尼耐药或不耐受的胃肠间质瘤中国患者的疗效和安全性。
Future Oncol. 2012 May;8(5):617-24. doi: 10.2217/fon.12.29.
9
Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.手术干预治疗伊马替尼和舒尼替尼耐药的胃肠道间质瘤。
Int J Clin Oncol. 2011 Dec;16(6):741-5. doi: 10.1007/s10147-011-0208-4. Epub 2011 Mar 12.
10
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.原发性和继发性激酶基因型与舒尼替尼在伊马替尼耐药胃肠道间质瘤中的生物学和临床活性相关。
J Clin Oncol. 2008 Nov 20;26(33):5352-9. doi: 10.1200/JCO.2007.15.7461. Epub 2008 Oct 27.
引用本文的文献
1
Transcriptomic study of gastrointestinal stromal tumors with liver metastasis.伴有肝转移的胃肠道间质瘤的转录组学研究
Front Genet. 2023 Feb 23;14:1007135. doi: 10.3389/fgene.2023.1007135. eCollection 2023.
2
Secreted protein acidic and rich in cysteine-like 1 suppresses metastasis in gastric stromal tumors.富含半胱氨酸样酸性分泌蛋白1抑制胃间质瘤转移。
BMC Gastroenterol. 2018 Jul 4;18(1):105. doi: 10.1186/s12876-018-0833-8.
3
Evaluation of the relationship between c-Kit expression and mean platelet volume in classic Kaposi's sarcoma.经典型卡波西肉瘤中c-Kit表达与平均血小板体积之间关系的评估。
An Bras Dermatol. 2016 Jul-Aug;91(4):430-5. doi: 10.1590/abd1806-4841.20164331.
4
Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.舒尼替尼可减少髓源性抑制细胞，并与癌症疫苗协同作用，以增强抗原特异性免疫反应并根除肿瘤。
Oncoimmunology. 2015 Jan 7;4(3):e989764. doi: 10.4161/2162402X.2014.989764. eCollection 2015 Mar.
5
A comparative study between Embosphere(®) and conventional transcatheter arterial chemoembolization for treatment of unresectable liver metastasis from GIST.对比研究 EmboSphere（®）与常规经导管动脉化疗栓塞治疗不可切除的胃肠道间质瘤肝转移。
Chin J Cancer Res. 2014 Feb;26(1):124-31. doi: 10.3978/j.issn.1000-9604.2014.02.11.
6
Development of enterohepatic fistula after embolization in ileal gastrointestinal stromal tumor: a case report.肠肝内瘘在回肠胃肠道间质瘤栓塞治疗后发生：一例报告。
World J Gastroenterol. 2013 Nov 21;19(43):7816-9. doi: 10.3748/wjg.v19.i43.7816.
7
[18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.[18F]-FLT 正电子发射断层扫描可用于对新型药物 GDC-0941 抑制 PI3-激酶后敏感肿瘤的反应进行成像。
Mol Cancer Ther. 2013 May;12(5):819-28. doi: 10.1158/1535-7163.MCT-12-0905. Epub 2013 Feb 20.
8
Transcatheter arterial chemoembolization for gastrointestinal stromal tumors with liver metastases.经导管动脉化疗栓塞治疗胃肠道间质瘤肝转移。
World J Gastroenterol. 2012 Nov 14;18(42):6134-40. doi: 10.3748/wjg.v18.i42.6134.
9
Lipomatous hemangiopericytoma of the stomach: a case report and a review of literature.胃脂肪肉瘤样血管外皮细胞瘤：一例报告及文献复习。
World J Gastroenterol. 2011 Nov 21;17(43):4835-8. doi: 10.3748/wjg.v17.i43.4835.
10
An essential role of PDCD4 in progression and malignant proliferation of gastrointestinal stromal tumors.PDCD4 在胃肠道间质瘤的进展和恶性增殖中具有重要作用。
Med Oncol. 2012 Sep;29(3):1758-64. doi: 10.1007/s12032-011-0042-6. Epub 2011 Aug 18.
本文引用的文献
1
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.尼洛替尼用于治疗对伊马替尼和舒尼替尼均耐药的晚期胃肠道间质瘤。
Eur J Cancer. 2009 Sep;45(13):2293-7. doi: 10.1016/j.ejca.2009.04.030. Epub 2009 May 19.
2
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.伊马替尼的血浆水平与不可切除/转移性胃肠道间质瘤患者的临床获益相关。
J Clin Oncol. 2009 Jul 1;27(19):3141-7. doi: 10.1200/JCO.2008.20.4818. Epub 2009 May 18.
3
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.局部原发性胃肠间质瘤切除术后辅助使用甲磺酸伊马替尼：一项随机、双盲、安慰剂对照试验。
Lancet. 2009 Mar 28;373(9669):1097-104. doi: 10.1016/S0140-6736(09)60500-6. Epub 2009 Mar 18.
4
Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).术前使用甲磺酸伊马替尼治疗不可切除或局部晚期原发性胃肠道间质瘤（GIST）。
Eur J Surg Oncol. 2009 Jul;35(7):739-45. doi: 10.1016/j.ejso.2008.11.005. Epub 2008 Dec 24.
5
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.原发性和继发性激酶基因型与舒尼替尼在伊马替尼耐药胃肠道间质瘤中的生物学和临床活性相关。
J Clin Oncol. 2008 Nov 20;26(33):5352-9. doi: 10.1200/JCO.2007.15.7461. Epub 2008 Oct 27.
6
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.北美协作组甲磺酸伊马替尼治疗晚期胃肠道间质瘤的III期试验中激酶基因型与临床结局的相关性：癌症与白血病B组及西南肿瘤协作组的CALGB 150105研究
J Clin Oncol. 2008 Nov 20;26(33):5360-7. doi: 10.1200/JCO.2008.17.4284. Epub 2008 Oct 27.
7
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.甲磺酸伊马替尼新辅助/辅助治疗晚期原发性及转移性/复发性可切除胃肠道间质瘤（GIST）的II期试验：RTOG 0132/ACRIN 6665的早期结果
J Surg Oncol. 2009 Jan 1;99(1):42-7. doi: 10.1002/jso.21160.
8
Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.致癌性KIT和PDGFRA突变在胃肠道间质瘤中的临床意义
Histopathology. 2008 Sep;53(3):245-66. doi: 10.1111/j.1365-2559.2008.02977.x. Epub 2008 Feb 28.
9
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.III期随机组间试验，评估甲磺酸伊马替尼在两个剂量水平对表达kit受体酪氨酸激酶的不可切除或转移性胃肠道间质瘤患者的疗效：S0033。
J Clin Oncol. 2008 Feb 1;26(4):626-32. doi: 10.1200/JCO.2007.13.4452.
10
Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.PTK787/ZK222584治疗对甲磺酸伊马替尼耐药的转移性胃肠道间质瘤的II期开放标签研究。
Ann Oncol. 2008 Jan;19(1):173-7. doi: 10.1093/annonc/mdm419. Epub 2007 Aug 14.
Zotero 插件